BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24582492)

  • 1. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach.
    Bertani E; Fazio N; Botteri E; Chiappa A; Falconi M; Grana C; Bodei L; Papis D; Spada F; Bazolli B; Andreoni B
    Surgery; 2014 Apr; 155(4):607-14. PubMed ID: 24582492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.
    Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y
    JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.
    Bertani E; Fazio N; Radice D; Zardini C; Spinoglio G; Chiappa A; Ribero D; Biffi R; Partelli S; Falconi M
    Eur J Surg Oncol; 2017 Feb; 43(2):372-379. PubMed ID: 27742480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended surgery for advanced pancreatic endocrine tumours.
    Kleine M; Schrem H; Vondran FW; Krech T; Klempnauer J; Bektas H
    Br J Surg; 2012 Jan; 99(1):88-94. PubMed ID: 22135173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
    Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
    Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review.
    Capurso G; Bettini R; Rinzivillo M; Boninsegna L; Delle Fave G; Falconi M
    Neuroendocrinology; 2011; 93(4):223-9. PubMed ID: 21358176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
    Citterio D; Pusceddu S; Facciorusso A; Coppa J; Milione M; Buzzoni R; Bongini M; deBraud F; Mazzaferro V
    Eur J Surg Oncol; 2017 Feb; 43(2):380-387. PubMed ID: 27956320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.
    Bertani E; Falconi M; Grana C; Botteri E; Chiappa A; Misitano P; Spada F; Ravizza D; Bazolli B; Fazio N
    Int J Surg; 2015 Aug; 20():58-64. PubMed ID: 26074290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
    Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
    Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study.
    Le Treut YP; Grégoire E; Klempnauer J; Belghiti J; Jouve E; Lerut J; Castaing D; Soubrane O; Boillot O; Mantion G; Homayounfar K; Bustamante M; Azoulay D; Wolf P; Krawczyk M; Pascher A; Suc B; Chiche L; de Urbina JO; Mejzlik V; Pascual M; Lodge JP; Gruttadauria S; Paye F; Pruvot FR; Thorban S; Foss A; Adam R;
    Ann Surg; 2013 May; 257(5):807-15. PubMed ID: 23532105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
    Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases.
    Partelli S; Inama M; Rinke A; Begum N; Valente R; Fendrich V; Tamburrino D; Keck T; Caplin ME; Bartsch D; Thirlwell C; Fusai G; Falconi M
    Neuroendocrinology; 2015; 102(1-2):68-76. PubMed ID: 26043944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic neuroendocrine metastases: does intervention alter outcomes?
    Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
    J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Transplant for Metastatic Neuroendocrine Tumors: A Single-Center Experience in Hungary.
    Korda D; Doros A; Piros L; Gerlei Z; Haboub-Sandil A; Mándli T; Fazakas J; Deák ÁP; Máthé Z
    Transplant Proc; 2019 May; 51(4):1251-1253. PubMed ID: 31101208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.